

## Diagnostics Advisory Committee Interests Register

Register last updated: November 2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Brian Shine	Chair, Consultant Chemical Pathologist, John Radcliffe Hospital	-	None	-	Feb 2023	-	Declare and participate.
Anne Scott	Consultant Cardiologist, NHS Forth Valley	-	None	-	Oct 2023	-	Declare and participate.
Diane Davies	Standing committee lay member	-	None	-	Oct 2023	-	Declare and participate.
Ghada Ahmed	Consultant in Acute Medicine, Barking, Havering, and Redbridge University Hospitals NHS trust	-	None	-	Oct 2023	-	Declare and participate.
John Cairns	Professor of Health Economics, London School of Hygiene and Tropical Medicine	Financial	Advice to SOBI regarding the economic evaluation of loncastuximab tesarine for treating DLBCL	Jan 2023	Oct 2023	March 2023	Declare and participate.
John Cairns	Professor of Health Economics, London School of Hygiene and Tropical Medicine	Financial	Advice to SOBI regarding economic evaluation of efanesoctocog alfa for treating haemophilia A.	May 2023	Oct 2023	July 2023	Declare and participate.
John Cairns	Professor of Health Economics, London School of Hygiene and Tropical Medicine	Financial	Participate in steering group for study of preferences for pain relief funded by Grünenthal. Interest arose: April 2023 - ongoing	April 2023	Oct 2023	Ongoing	Declare and participate.

Jonathan Weir-McCall	University Lecturer and Honorary Consultant Cardiothoracic Radiologist, Department of Radiology at the University of Cambridge, and Royal Papworth Hospital	-	None	-	Nov 2023	-	Declare and participate.
Joy Allen	Health Economics Manager, Roche Diagnostics UK and Ireland	Financial	I am an employee of Roche Diagnostics.		Nov 2023	Ongoing	Participate in part 1 only. <b>Confirmed by Chair, AD and PD 27 November 2023.</b>
Keith Abrams	Professor of Statistics & Data Science in the Department of Statistics, University of Warwick & NIHR Senior Investigator Emeritus, and Hon Prof in the Centre for Health Economics at the University of York	Non-financial professional	<p>The OPTIMA trial is co-ordinated by Warwick CTU, and as such my counselling about the implications of our decision on the trial may be perceived as a conflict.</p> <p>As the trial has recruited 3900/4500 patients even if it stopped following any final DAC decision it would not materially have any impact on WCTU.</p> <p>I do not have any formal relationship with Warwick CTU (but I am an Adjunct [internal honorary] Professor in Warwick Medical School – which they are also part of), though I do collaborate with colleagues in Warwick CTU (mainly, but not exclusively, on methodological projects) and have not had any involvement with the OPTIMA trial.</p>		Oct 2023		<p>Declare and participate</p> <p><i>Confirmed by Chair and AD 30 October 2023.</i></p>

Keith Abrams	Professor of Statistics & Data Science in the Department of Statistics, University of Warwick & NIHR Senior Investigator Emeritus, and Hon Prof in the Centre for Health Economics at the University of York	Financial	Partner & Director, Visible Analytics Limited - a HTA Consultancy company, but I have not been involved in any projects which involve a diagnostic technology. However, Visible Analytics is undertaking a project for Echosens on evaluating FibroScan for assessing liver fibrosis and cirrhosis in primary care. I am not involved in the project in any way and measures have been taken (for example I do not have access to the project folder etc) to avoid potential conflicts.	May 2019	Oct 2023	Ongoing	Declare and participate.
Matt Stevenson	Professor of Health Technology Assessment, ScHARR	Non-financial professional	The work has been undertaken by SCHARR-TAG (and I'm the Director of SCHARR-TAG). I have not participated in this work however.		Oct 2023	Ongoing	Declare and participate.
Michael Messenger	Senior Regulatory Affairs Advisor, FIND	Direct non-financial	I was a co-investigator on a Myriad Genetics funded health economics evaluation at the University of Leeds, evaluating the impact of an unrelated test, Prolaris for prostate cancer prognosis.  As part of this, Myriad Genetics paid for my lunch (<£20) on 3rd October 2017 to discuss the Prolaris project.	Jul 2014	Nov 2023		Declare and participate
Michael Messenger	Senior Regulatory Affairs Advisor, FIND	Indirect – Non-Financial	Former colleagues from the NIHR MIC in Leeds, for which I am was Deputy Director, are co-	Jun 2014	Nov 2023	Oct 2020	Declare and participate

			investigators on the OPTIMA trial				
Michael Messenger	Senior Regulatory Affairs Advisor, FIND	Indirect – Financial	Myriad Genetics, Roche Diagnostics and Genomic Health sponsored the NIHR Leeds In Vitro Diagnostic Launch Event.	Mar 2018	Nov 2023	Mar 2018	Declare and participate
Neil Hawkins	Professor of Health Technology Assessment, University of Glasgow	Financial	I am a director of a company providing consultancy services to the biomedical and pharmaceutical sectors. No services have been provided to stakeholders associated with the current appraisal		Oct 2023	Ongoing	Declare and participate.
Patrick McGinley	Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust	Financial	Honorary Treasurer of ASO		Oct 2023	Ongoing	Declare and participate.
Patrick McGinley	Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust	Non-financial professional	Member of the strategic committee of APPG on Obesity		Oct 2023	Ongoing	Declare and participate.
Patrick McGinley	Head of Costing and Service Line Reporting, Maidstone and Tunbridge Wells NHS Trust	Financial	Honoraria received from MTech Access for provision of advice on NHS finance regime and changes.		Nov 2023		Declare and participate
Radha Ramachandran	Consultant Chemical Pathology and Metabolic Medicine, Guys and St Thomas' NHS Foundation Trust	-	None	-	Oct 2023	-	Declare and participate.

Rashmi Kumar	Standing committee lay member	-	None	-	Oct 2023	-	Declare and participate.
Rebecca Allcock	Consultant Clinical Biochemist, Lancashire Teaching Hospitals	-	None	-	Oct 2023	-	Declare and participate.
Sam Creavin	GP and NIHR Clinical Lecturer, University of Bristol	-	None	-	Oct 2023	-	Declare and participate.
Alex Novak	Consultant in Emergency Medicine and Ambulatory Care, Oxford University Hospitals NHSFT	-	None	-	Oct 2023	-	Declare and participate.
Farai Goromonzi	Senior Market Access Manager, Zoll	-	None	-	Oct 2023	-	Declare and participate.
Michael Morton	GP	-	None	-	Oct 2023	-	Declare and participate.

## Diagnostics Advisory Committee Interests Register

Register last updated: November 2023

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Britta Stordal	Senior Lecturer in Medical Sciences, Middlesex University London	Financial	Senior Lecturer Middlesex University – Primary Employment	2014	February 2023	Current	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Britta Stordal	Senior Lecturer in Medical Sciences, Middlesex University London	Financial	EU Research Executive Agency – Grant Review – Occasional Contract Work reviewing grants.	2010	February 2023	Current	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Britta Stordal	Senior Lecturer in Medical Sciences, Middlesex University London	Non – financial professional and personal	Vice Chair and Head of Science and Public Affairs Committee Breast Cancer UK (Cancer prevention charity, does not work in the area of cancer treatment/diagnostics)	2021	February 2023	Current	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Britta Stordal	Senior Lecturer in Medical Sciences, Middlesex University London	Non – financial professional and personal	Lay Member of Clinical Oncology Academic Committee – Royal Collage of Radiologists.	2022	February 2023	Current	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>

Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Financial	Roche – advisory boards, speaker fees, conference support and expenses	June 2022	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Financial	MSD – advisory boards and speaker fees	Sept 2022	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Financial	Lilly – advisory boards, conference support and expenses	June 2022	February 2023	Dec 2022	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Financial	BD -Speaker fees	May 2022	February 2023	May 2022	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>

Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Financial	Novartis – institutional research funding	Jan 2020	February 2023	Jan 2022	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Chair, National Cancer Research Institute Breast Research Group	Jan 2020	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Royal College of Surgeons, Breast Surgical Specialty Lead	Nov 2017	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Member OPTIMA Trial Management Group and Surgical Lead.	2018	February 2023	Ongoing	Declare and remain for <b>part 1 only</b> . <i>Considered on appointment, outcome confirmed October 2023 by the Chair.</i>



Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Member, Association of Breast Surgery Academic and Research Committee	2013	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Trustee, Action Cancer	2019	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Stuart McIntosh	Clinical Reader in Surgical Oncology, Queen's University Belfast Honorary Consultant Breast Surgeon, Belfast Health & Social Care Trust	Non – financial professional and personal	Member, NIHR HTA General Funding Committee	June 2022	February 2023	Ongoing	Declare and participate. <i>Considered on appointment in March 2023 by Chair and Associate Director.</i>
Caroline Graham	Lay SCM	N/A	None	N/A	April 2023	N/A	Declare and participate.  <i>Confirmed by Chair and Associate Director on appointment May 2023.</i>

Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking – Astra Zeneca		Jul 2023	Ongoing contract	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / advisory board - Lilly		Jul 2023	Ongoing contract	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / advisory board - Roche		Jul 2023	Ongoing contract	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / ESMO breast conference sponsorship - Pfizer	5/4/22	Jul 2023	13/5/23	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / advisory board - Novartis	5/5/23	Jul 2023	5/5/23	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / advisory board - Seagen	11/11/22	Jul 2023	13/7/23	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>

Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking - Gilead	8/5/22	Jul 2023	13/3/23	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	Honoraria for speaking / advisory board – Chugai	27/5/22	Jul 2023	28/2/23	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Financial	BOPA Conference sponsorship - Amgen	Oct 2022	Jul 2023	Oct 2022	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Non – financial professional and personal	British Oncology Pharmacy Association – member and member of the Research Committee		Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Non – financial professional and personal	Audit Advisory Committee member for National audit of Primary Breast cancer (NAoPri) and National audit of Metastatic Breast cancer (NAoMe)		Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Suzanne Frank	Advanced specialist breast cancer pharmacist, The Christie Hospital NHS Trust	Non – financial professional and personal	Steering group committee member for MO43110 ProHER trial sponsored by Roche to determine whether people with early or locally advanced/inflammatory		Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>

			HER2+ breast cancer prefer to receive combined pertuzumab and trastuzumab treatment at home or in a hospital setting				
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Financial	Advisory Board-Stemline Therapeutics Advise on developing ESR1 testing. ESR1 is a genetic biomarker that guides use of the drug elacestrant	June 2023	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Financial	Advisory Board-Roche Advise on the use of mass spectrometry to guide endocrine therapy in breast cancer	July 2023	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Financial	Payment for speaking engagement Novartis For talk at UK Oncology Masterclass on Hot Topics in Genetics	June 2023	Jul 2023	June 2023	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Non – financial professional and personal	Honorary Professor, Swansea University	June 2021	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Non – financial professional and personal	Co-author on paper 'A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who	June 2022	Jul 2023	June 2022	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>

			underwent initial OncotypeDX® testing to guide adjuvant chemotherapy decisions.				
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Non – financial professional and personal	Local sub investigator on OPTIMA study This study aims to evaluate a gene assay to guide chemotherapy decisions in high risk breast cancer.	June 2017	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Mark Davies	Consultant in Medical Oncology, Swansea Bay University Health Board	Non – financial professional and personal	Had been a local sub investigator on the Holt study.		Nov 2023		Declare and participate.  <i>Declared and considered at committee meeting November 2023.</i>
Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Financial	Private Practice Cancer Centre London	Jan 2012	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Financial	Occasional payments or benefits in kind such as Hospitality.	Roche ASCO June 2023	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Financial	ESMO Advisory Boards	Roche ESMO Sept 2023	Jul 2023	Ongoing	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>

Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Non – financial professional and personal	Future Dreams Fundraising and Lunch Lecture	October 2017	Jul 2023	October 2017	Declare and participate. <i>Considered on appointment in August 2023 by Chair and Associate Director.</i>
Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Non – financial professional and personal	My trust is running the OPTIMA study.		Oct 2023	Ongoing	Declare and participate.
Muireann Kelleher	Consultant Medical Oncologist, St George's University Hospital NHS Foundation Trust	Non – financial professional and personal	My trust has declined entering into an agreement with EXACT sciences to procure OncotypeDX for node positive cases.		Oct 2023		Declare and participate.